Role of chemotherapy in the management of epithelial ovarian cancer

References

• Eisenkop SM, Spiritos N. What are the current surgical objectives, strategies and technical capabilities of gynecologists treating advanced epithelial ovarian cancer? Gynecol. Oncol.1(82), 489–497 (2001).
   Google Scholar
• Trimbos B, Bolis G. Guidelines for surgical staging of ovarian cancer. Obstet. Gynecol. Surv.49, 814–816 (1994).
   PubMedGoogle Scholar
• Sakurai S, Shimizu Y, Utsugi K et al. Validity of complete para-aortic and pelvic lymphadenectomy in apparent Stage I (pT1) ovarian carcinoma. Proc. Am. Soc. Clin. Oncol.21(1) (2002) (Abstract 801).
   Google Scholar
• Cass I, Li AJ, Runowicz CD et al. Pattern of lymph node metastases in clinically unilateral Stage I invasive epithelial ovarian carcinomas. Gynecol. Oncol.80, 56–61 (2001).
   PubMedGoogle Scholar
• Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol.106(11), 1130–1136 (1999).
   PubMedGoogle Scholar
• Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer – Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J. Natl Cancer Inst.95(2), 113–125 (2003).
   PubMed Web of Science ®Google Scholar
• Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl Cancer Inst.95(2), 105–112 (2003).
   PubMed Web of Science ®Google Scholar
• International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet360, 505–515 (2002).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage 3 and 4 ovarian cancer. N. Engl. J. Med.334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Mäenpää JU, Ala-Fossi S-L, Kivinen ST et al. Docetaxel and irinotecan in the second-line treatment of ovarian cancer: final results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 894).
   Google Scholar
• Nogue M, Cicera L, Arcusa A et al. Phase II study of gemcitabine and cisplatin in chemo-naive patients with advanced epithelial ovarian cancer. Anticancer Drugs13, 839–845 (2002).
   PubMedGoogle Scholar
• du Bois A, Luck HJ, Bauknecht T et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a Phase I/II study of the Arbeitsgemeinschaft Gynekologische Onkologie Ovarian Cancer Study Group. J. Clin. Oncol.17(1), 46–51 (1999).
   PubMedGoogle Scholar
• Vergote I, Kristensen G, Stuart G, Aavall-Lundquist E, Kaern J, Eisenhauer E. First line treatment of ovarian cancer FIGO Stages IIB–IV with paclitaxel epirubicin–carboplatin (TEC) vs. paclitaxel–carboplatin (TC). Interim results of an NSGO-EORTC GCG-NCIC CTG Intergroup Phase III study. Int. J. Gyn. Cancer13(Suppl. 2), 172–177 (2003).
   PubMedGoogle Scholar
• ICON Collaborators. ICON2: randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer Lancet352, 1571–1576 (1998).
   Google Scholar
• Cassidy J, Vergote I, Bertelsen K, Stuart G, Baron B, Piccart M. Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin (TP) regimen over the cyclophosphamide–cisplatin (CP) combination in advanced ovarian cancer (AOC). Int. J. Gyn. Cancer12(5), 558–559 (2002).
   Google Scholar
• Advanced Ovarian Cancer Trialists Groups. Chemotherapy in advanced ovarian cancer; an overview of randomized clinical trials. Br. Med. J.303, 884–893 (1991).
   PubMed Web of Science ®Google Scholar
• du Bois A, Lueck HJ, Meier W et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc. Am. Soc. Clin. Oncol.18, 356a (1999) (Abstract 1374).
   Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol.18, 3084–3092 (2000).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Fowler J et al. Randomized Phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG-158). Proc. Am. Soc. Clin. Oncol.18, 356a (1999) (Abstract 1373).
   Google Scholar
• Muggia FM, Braly PS, Brady MF et al. Phase III study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal Stage III or IV ovarian cancer: a Gynecologic Oncology Group Study (132). J. Clin. Oncol.18, 106–115 (2000).
   PubMed Web of Science ®Google Scholar
• Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel–carboplatin (DC) vs. paclitaxel–carboplatin (PC) in epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol.21, 202a (2002) (Abstract 804).
   Google Scholar
• Kristensen G, Vergote I, Stuart G et al. First line treatment of ovarian cancer FIGO stages IB–IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup Phase III trial. Proc. Am. Soc. Clin. Oncol.21, 202a (2002) (Abstract 805).
   Google Scholar
• du Bois A, Weber B, Pfisterer J et al. Epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (PC) in first-line treatment of ovarian cancer FIGO Stages IIb–IV. Interim results of an AGO-GINECO Intergroup Phase III Trial. Proc. Am. Soc. Clin. Oncol.20, 202a (2001) (Abstract 805).
   Google Scholar
• Rustin GJ, Atkinson RJ, Osborne R et al. Preliminary results of SCOTROC 2a, a randomized feasibility study of carboplatin (C) then sequential docetaxel (D) or two schedules of docetaxel + gemcitabine (G) in ovarian/mullerian cancers. Proc. Am. Soc. Clin. Oncol.21, 203a (2002) (Abstract 810).
   Google Scholar
• Jayson GC, Maenpaa J, Wilkinson PM et al. Randomized feasibility study of Carboplatin followed by Taxotere or Taxotere/Irinotecan in ovarian cancer (SCOTROC IIB). Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 1805).
   Google Scholar
• Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a South West Oncology Group and Gynecologic Oncology Group Trial. J. Clin. Oncol.21, 2460–2465 (2003).
   Google Scholar
• Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume Stage III ovarian carcinoma: an intergroup study of the GOG, SWOG and ECOG. J. Clin. Oncol.19, 1001–1007 (2001).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for Stage III ovarian cancer. N. Engl. J. Med.335, 1950–1955 (1996).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy BN, Baergen R et al. Randomized Phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynaecologic Oncology Group trial (GOG-172). Proc. Am. Soc. Clin. Oncol.21, 201a (2002) (Abstract 803).
   Web of Science ®Google Scholar
• Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer13(Suppl. 2), 196–203 (2003).
   PubMed Web of Science ®Google Scholar
• Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Natl Cancer Inst. Monogram42, 101 (1975).
   PubMedGoogle Scholar
• Hunter RW, Alexander NDE, Soutter WP et al. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol.166, 504–511 (1992).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK et al. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis of 6,848 patients. Proc. Am. Soc. Clin. Oncol.20, 202a (2001) (Abstract 807).
   Google Scholar
• van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Co-operative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med.332, 629–634 (1995).
   PubMed Web of Science ®Google Scholar
• Rose PG, Nerenstone S, Brady M et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med.351, 2489–2497 (2004).
   PubMed Web of Science ®Google Scholar
• Hess V, A’Hern R, Nasir N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J. Clin. Oncol.22, 1040–1044 (2004).
   PubMed Web of Science ®Google Scholar
• McGuire V, Jesser CA, Whittemore AS. Survival among US women with invasive epithelial ovarian cancer. Gynecol. Oncol.84, 399–403 (2002).
   PubMedGoogle Scholar
• Aoki Y, Yahata T, Fujita K et al. Irinotecan and mitomycin C in ovarian clear cell adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 5129).
   PubMedGoogle Scholar
• Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol. Cell Endocrinol.202, 97–99 (2003).
   PubMed Web of Science ®Google Scholar
• Benoit M, Hannigan E, Smith RP, Smith ER, Byers LJ. Primary gastrointestinal cancers presenting as gynecologic malignancies. Gynecol. Oncol.95, 388–392 (2004).
   PubMedGoogle Scholar
• Shimizu Y, Umezawa S, Hasumi K. A Phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann. Acad. Med. Singapore27, 650–656 (1998).
   PubMedGoogle Scholar
• Vermorken JB, Eisenhauer E, Lu F et al. Prognostic features of importance for Phase II studies in platinum pre-treated ovarian cancer patients abstract. Proc. Int. Congress Anticancer Treat. (1996) (Abstract 130).
   Google Scholar
• Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol.9, 389–393 (1991).
   PubMed Web of Science ®Google Scholar
• Markman M, Markman J, Webster K et al. Duration of response to second line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol.22, 3120–3125 (2004).
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet361(9375), 2099–2106 (2003).
   PubMed Web of Science ®Google Scholar
• Pfisterer JF, Plante M, Vergote I et al. Gemcitabine carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian carcinoma. Results of a GCIG randomized Phase III trial of the AGO OVAR, NCI-C CTG and EORTC GCG. Proc. Am. Soc. Clin. Oncol.23, 449a (2004) (Abstract 5005).
   Google Scholar
• González A, Calvo E, Bover I et al. Randomized Phase II study of carboplatin versus paclitaxel–carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. A GEICO study (Spanish Group for investigation on Ovarian Carcinoma). Proc. Am. Soc. Clin. Oncol. (Abstract 1812) (2003).
   PubMedGoogle Scholar
• Leea CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol. Oncol.95, 370–376 (2004).
   PubMedGoogle Scholar
• van der Burg MEL, Vergote I, Burger CW, van der Gaast A. Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. Proc. Am. Soc. Clin. Oncol.23, 462a (2004) (Abstract 5058).
   Google Scholar
• Gordon A, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a Phase III randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol.15, 100–103 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon A, Fleagle JT, Guthrie D, Parkin D, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma, a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore ME, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol.15, 2183–2193 (1997).
   PubMed Web of Science ®Google Scholar
• O’Byrne K, Bliss P, Graham JD et al. A Phase III study of doxil/caelyx versus paclitaxel in platinum treated taxane-naive relapsed ovarian cancer. Proc. Am. Soc. Clin. Oncol.21, 203a (2002) (Abstract 808).
   Google Scholar
• Morris T. Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol.90, S34–S38 (2003).
   PubMed Web of Science ®Google Scholar
• O’Malley D, Makkenchery A, Tangir M et al. Retrospective analysis of topotecan administered weekly in heavily pre-treated recurrent epithelial ovarian carcinoma patients. Proc. Am. Soc. Clin. Oncol.23, 467a (2004) (Abstract 5079).
   Google Scholar